The drug Liel (topical testosterone) was withdrawn from FDA consideration due to unmet efficacy endpoints, despite showing no increased risk for cardiovascular disease, breast cancer, or metabolic markers in women with cardiovascular risk factors over seven years of data.

“and it didn't have efficacy correct it wasn't right so it was it was called liel and they um they they looked at the data for out to five years and had like seven years of women patient data research and it didn't show any hits for being unsafe and it was loaded for women with cardiovascular risk factors um there was no increased rates above Baseline rates of cardiovascular disease of breast cancer of intermediate markers for metabolic or cardiovascular risk like A1C lipids inflammatory markers but um and they reached the therapeutic level in the blood right so they felt that they could clearly state that this represented safety data y but the efficacy hit wasn't met and so they they did not take it further to the FDA unfortunately”